EU and US could reach trade deal this weekend - Reuters
IRVINE, Calif. - ReShape Lifesciences Inc. (NASDAQ:RSLS), a medical device company with a market capitalization of $5.73 million and annual revenue of $7.17 million, announced Tuesday that the U.S. Patent and Trademark Office will issue a new patent on July 8, 2025, covering the company’s intragastric balloon system.
The patent, U.S. Patent 12,350,179, provides protection for a swallowable capsule with self-sealing fill valve and degradable release valve designed to deflate approximately three months after inflation with saline liquid. The device is configured for natural excretion following deflation.
According to the company, the patent will provide protection until at least January 2031, with potential for extension. This adds to ReShape’s intellectual property portfolio, which now includes over 50 patents specifically related to intragastric balloon technology and more than 160 issued and pending patents across various technologies.
"This pivotal patent represents a significant milestone, further reinforcing our intellectual property portfolio and providing broad protection for our innovative intragastric balloon system," said Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.
The company noted in its press release statement that it has previously entered into an asset purchase agreement with Biorad Medisys to sell substantially all of its assets, including the Obalon Gastric Balloon System referenced in the patent announcement.
ReShape Lifesciences focuses on weight loss and metabolic health solutions, offering products that manage and treat obesity and metabolic disease. The company currently trades at a low revenue valuation multiple, according to InvestingPro analysis.
In other recent news, ReShape Lifesciences has successfully regained compliance with Nasdaq’s stockholders’ equity requirement, following two equity offerings that raised approximately $6.28 million. This move helps the company avoid a potential delisting from the exchange. Additionally, ReShape has announced a strategic workforce reduction expected to save over $750,000 annually. The company also reported progress in finalizing its merger agreement with Vyome Therapeutics and an asset sale to Biorad Medisys, with a shareholder meeting scheduled for July 24, 2025, to vote on these transactions.
ReShape Lifesciences has been granted an Australian patent for its Diabetes Neuromodulation technology, which offers a novel approach to Type 2 diabetes treatment through vagus nerve stimulation. The company has also signed an exclusive U.S. distribution agreement with Recon Supply to distribute its medical devices across Veterans Administration and Department of Defense healthcare systems. This agreement aims to expand the reach of ReShape’s technologies, including the STIMEL-03 neuromuscular rehabilitation device and the Lap-Band 2.0 FLEX weight loss system. The company remains focused on its digital marketing campaigns and international expansion efforts, particularly in Canada.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.